A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers

Virus Research

Volumn 170, Issue 1-2, 2012, Pages 44-52

  Radaelli, Antonia ^a   De Giuli Morghen, Carlo ^a   Zanotto, Carlo ^a   Pacchioni, Sole ^a   Bissa, Massimiliano ^a   Franconi, Rosella ^b   Massa, Silvia ^b   Paolini, Francesca ^c   Muller, Antonio ^c   Venuti, Aldo ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b ENEA C R CASACCIA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Fowlpox virus; HPV; Mutated E7GGG oncoprotein; Prime boost immunization; Recombinant vaccines

Indexed keywords

ANTIBODY; DNA PROTEIN E7 GLYCYLGLYCYLGLYCINE; DNA VACCINE; FOWLPOX VIRUS PROTEIN E7 GLYCYLGLYCYLGLYCINE; PROTEIN E7; PROTEIN E7 ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; DRUG EFFICACY; FEMALE; FOWLPOX VIRUS; HETEROLOGOUS EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; VIRUS RECOMBINANT;

ANIMALS; CANCER VACCINES; CELL LINE; FEMALE; FOWLPOX VIRUS; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY; MICE; MUTANT PROTEINS; NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; PLASMIDS; TRANSGENES; VACCINES, DNA;

FOWLPOX VIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

EID: 84870406796     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.08.007     Document Type: Article

References (65)

1. Acres B., Bonnefoy J.Y. Clinical development of MVA-based therapeutic cancer vaccines. Expert Reviews on Vaccines 2008, 7:889-893.
2. Baldwin P.J., van der Burg S.H., Boswell C.M., Offringa R., Hickling J.K., Dobson J., Roberts J.S., Latimer J.A., Moseley R.P., Coleman N., Stanley M.A., Sterling J.C. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clinical Cancer Research 2003, 9:5205-5213.
3. Baxby D., Paoletti E. Potential use of nonreplicating vectors as recombinant vaccines. Vaccine 1992, 10:8-9.
4. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. Journal of General Virology 1998, 79:1159-1167.
5. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E., Rutherford E., Hickling J.K., Inglis S.C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523-1527.
6. Campo M.S., Grindlay G.J., O'Neil B.W., Chandrachud L.M., McGarvie G.M., Jarrett W.F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. Journal of General Virology 1993, 74:945-953.
7. Chen C.H., Wang T.L., Hung C.F., Pardoll D.M., Wu T.C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000, 18:2015-2022.
8. Chen C.H., Wang T.L., Ji H., Hung C.F., Pardoll D.M., Cheng W.F., Ling M., Wu T.C. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Therapy 2001, 8:128-138.
9. Chen L., Mizuno M.T., Singhal M.C., Hu S.L., Galloway D.A., Hellström I., Hellström K.E. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. Journal of Immunology 1992, 148:2617-2621.
10. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. Journal of General Virology 1998, 79:347-352.
11. Duensing S., Münger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. International Journal of Cancer 2004, 109:157-162.
12. Edmonds C., Vousden K.H. A point mutational analysis of human papillomavirus type 16 E7 protein. Journal of Virology 1989, 63:2650-2656.
13. Eiben G.L., Da Silva D.M., Fausch S.C., Le Poole I.C., Nishimura M.I., Kast W.M. Cervical cancer vaccines: recent advances in HPV research. Viral Immunology 2003, 16:111-121.
14. Enserink M. Smallpox vaccines: looking beyond the next generation. Science 2004, 304:809.
15. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., ter Schegget J., Melief C.J., Kast W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. European Journal of Immunology 1993, 23:2242-2249.
16. Ferrier-Rembert A., Drillien R., Tournier J.N., Garin D., Crance J.M. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 2008, 26:1794-1804.
17. Fiander A.N., Tristram A., Davidson E.J., Tomlinson A.E., Man S., Baldwin P.J., Sterling J.C., Kitchener H.C. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. International Journal of Gynecological Cancer 2006, 16:1075-1081.
18. Frazer I.H., Leggatt G.R., Mattarollo S.R. Prevention and treatment of papillomavirus-related cancers through immunization. Annual Review of Immunology 2011, 29:111-138.
19. Frazer I.H., Thomas R., Zhou J., Leggatt G.R., Dunn L., McMillan N., Tindle R., Filgueira L., Manders P., Barnard P., Sharkey M. Potential strategies utilised by papillomavirus to evade host immunity. Immunological Reviews 1999, 168:131-142.
20. FUTURE II Study Group Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases 2007, 196:1431-1432.
21. Ghittoni R., Accardi R., Hasan U., Gheit T., Sylla B., Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40:1-13.
22. Gissmann, L., 2007. Human papillomavirus vaccines. 169-200.
23. Gissmann L., Nieto K. The therapeutic vaccine: is it feasible?. Archives of Medical Research 2009, 40:493-498.
24. Hagensee M.E., Yaegashi N., Galloway D.A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. Journal of Virology 1993, 67:315-322.
25. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255. HPV Vaccine Study group.
26. Harper D.M., Williams K.B. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discovery Medicine 2010, 10:7-17.
27. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO Journal 1989, 8:3905-3910.
28. Heck D.V., Yee C.L., Howley P.M., Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:4442-4446.
29. Hooper J.W., Ferro A.M., Golden J.W., Silvera P., Dudek J., Alterson K., Custer D.M., Rivers B., Morris J., Owens G., Smith J.F., Kamrud K.I. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 2010, 28:494-511.
30. Hooper J.W., Golden J.W., Ferro A.M., King A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007, 25:1814-1823.
31. Hsu K.F., Hung C.F., Cheng W.F., He L., Slater L.A., Ling M., Wu T.C. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Therapy 2001, 8:376-383.
32. Hung C.F., Ma B., Monie A., Tsen S.W., Wu T.C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opinion on Biological Therapy 2008, 8:421-439.
33. Johnston J.B., McFadden G. Poxvirus immunomodulatory strategies: current perspectives. Journal of Virology 2003, 77:6093-6100.
34. Kang T.H., Monie A., Wu L.S., Pang X., Hung C.F., Wu T.C. Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine 2011, 29:1082-1089.
35. Kanodia S., Da Silva D.M., Kast W.M. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. International Journal of Cancer 2008, 122:247-259.
36. Kennedy R.B., Ovsyannikova I., Poland G.A. Smallpox vaccines for biodefense. Vaccine 2009, 27:D73-D79.
37. Kirnbauer R., Booy N., Chengt D.R., Lowy D.R., Schiller J.T. Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:12180-12184.
38. Laurson J., Raj K. Localisation of human papillomavirus 16 E7 oncoprotein changes with cell confluence. PLoS One 2011, 6:e21501.
39. Lin Y.Y., Alphs H., Hung C.F., Roden R.B., Wu T.C. Vaccines against human papillomavirus. Frontiers in Bioscience 2007, 12:246-264.
40. Mackova J., Stasikova J., Kutinova L., Masin J., Hainz P., Simsova M., Gabriel P., Sebo P., Nemeckova S. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunology, Immunotherapy 2006, 55:39-46.
41. Massa S., Franconi R., Brandi R., Muller A., Mett V., Yusibov V., Venuti A. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 2007, 25:3018-3021.
42. Massa S., Paolini F., Spanò L., Franconi R., Venuti A. Mutants of plant genes for developing cancer vaccines. Human Vaccines 2011, 7:1-9.
43. Massa S., Simeone P., Muller A., Benvenuto E., Venuti A., Franconi R. Antitumor activity of DNA vaccines based on the Human Papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Human Gene Therapy 2008, 19:354-364.
44. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384:335-344.
45. Meneguzzi G., Cerni C., Kieny M.P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991, 181:62-69.
46. + T cells using an ELISPOT assay. Journal of Immunological Methods 1995, 181:45-54.
47. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. Journal of Virology 1989, 63:4417-4421.
48. Parks R.J., Krell P.J., Derbyshire J.B., Nagy E. Studies of fowlpox virus recombination in the generation of recombinant vaccines. Virus Research 1994, 32:283-297.
49. Pozzi E., Basavecchia V., Zanotto C., Pacchioni S., De Giuli Morghen C., Radaelli A. Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins. Journal of Virological Methods 2009, 158:184-189.
50. Radaelli A., Bonduelle O., Beggio P., Mahe B., Pozzi E., Elli V., Paganini M., Zanotto C., De Giuli Morghen C., Combadière B. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine 2007, 25:2128-2138.
51. Radaelli A., De Giuli Morghen C. Expression of HIV-1 envelope gene by recombinant avipoxvirus. Vaccine 1994, 12:1101-1109.
52. Radaelli A., Pozzi E., Pacchioni S., Zanotto C., De Giuli Morghen C. Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. Journal of Translational Medicine 2010, 8:40-51.
53. Rosel J.L., Earl P.L., Weir J., Moss B. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. Journal of Virology 1986, 60:436-449.
54. Skinner M.A., Laidlaw S.M., Eldaghayes I., Kaiser P., Cottingham M.G. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Review on Vaccines 2005, 4:63-76.
55. Smahel, Sima M., Ludvikov P., Marinov V., Pokorn I., Vonka Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 2003, 21:1125-1136.
56. Smahel M., Síma P., Ludvíková V., Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001, 281:231-238.
57. Smyth L.J., Van Poelgeest M.I., Davidson E.J., Kwappenberg K.M., Burt D., Sehr P., Pawlita M., Man S., Hickling J.K., Fiander A.N., Tristram A., Kitchener H.C., Offringa R., Stern P.L., van der Burg S.H. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clinical Cancer Research 2004, 10:2954-2961.
58. Taylor J., Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 1988, 6:466-468.
59. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in nonavian species. Vaccine 1988, 6:497-503.
60. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., Offringa R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001, 19:3652-3660.
61. Venuti A., Massa S., Mett V., Vedova L.D., Paolini F., Franconi R., Yusibov V. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 2009, 27:3395-3397.
62. Wilczynski S.P., Bergen S., Walker J., Liao S.Y., Pearlman L.F. Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Human Pathology 1988, 19:697-704.
63. Wlazlo A.P., Deng H., Giles-Davis W., Ertl H.C. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Therapy 2004, 11:457-464.
64. Zanotto C., Pozzi E., Pacchioni S., Bissa M., De Giuli Morghen C., Radaelli A. Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein. Journal of Translational Medicine 2011, 9:190-200.
65. Zanotto C., Pozzi E., Pacchioni S., Volonté L., De Giuli Morghen C., Radaelli A. Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. Antiviral Research 2010, 88:53-63.